About CytomX Therapeutics
CytomX Therapeutics is a biotechnology company that is dedicated to transforming lives with safer, more effective therapies. The company was founded in 2008 and has since been at the forefront of developing innovative cancer treatments that target specific proteins in the body.
One of the key features of CytomX Therapeutics is its Probody platform technology. This technology allows for the creation of highly targeted therapies that are designed to minimize side effects and maximize efficacy. Probody therapeutics are able to selectively bind to tumor cells while avoiding healthy tissue, which reduces toxicity and improves patient outcomes.
CytomX Therapeutics has a robust pipeline of Probody therapeutics in various stages of development. One such therapy is CX-072, which targets PD-L1, a protein found on some cancer cells that helps them evade detection by the immune system. By blocking PD-L1, CX-072 can help activate an immune response against cancer cells and potentially lead to tumor regression.
Another promising therapy in CytomX's pipeline is CX-2009, which targets CD166, a protein found on many solid tumors including breast, lung, and ovarian cancers. By targeting CD166 with a Probody therapeutic approach, CX-2009 has shown promising preclinical results as a potential treatment for these types of cancers.
In addition to its Probody platform technology and pipeline of innovative therapies, CytomX Therapeutics also has partnerships with several leading pharmaceutical companies including Bristol Myers Squibb and Amgen. These collaborations allow for further development and commercialization opportunities for CytomX's technologies.
Overall, CytomX Therapeutics is an exciting biotechnology company that is making significant strides towards transforming lives with safer and more effective cancer treatments through its innovative Probody platform technology. With its strong pipeline of therapies in development and strategic partnerships with industry leaders, it's clear that this company will continue to be at the forefront of advancing cancer care for years to come.